Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorolanib plus Toripalimab in Advanced Mucosal Melanoma
NCT03602547Phase 2Unknown
- Sponsor
- AnewPharma Company, Ltd.
- Start
- Jul 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorolanib in mucosal melanoma (MM), sponsored by AnewPharma Company, Ltd. Primary endpoint: Objective Response Rate at 12 months. Status: unknown.
02
Drugs
vorolanib
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT03602547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03602547.